GSK Outlines R&D Strategy at Guggenheim Healthcare Innovation Conference
GSK provided an update on its research and development priorities, focusing on human-validated targets and biomarker-led clinical trials for inflammatory diseases.
Stocks · News reference
ViiV Healthcare Presents Real-World HIV Data Showing Higher Adherence and Treatment Persistence With Long-Acting Cabotegravir/Rilpivirine Injections
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
GSK publishes provisional dividend dates for 2027
GSK plc has announced its indicative dividend schedule for the 2027 calendar year.
ViiV Healthcare Commits $100M Over Three Years Under Its U.S. Positive Action Program To Support Local HIV Organizations
GSK Chief Digital and Technology Officer Appointed to BAE Systems Board
Shobie Ramakrishnan, GSK's Chief Digital and Technology Officer, has been appointed as a non-executive director of BAE Systems plc, effective February 22, 2027.
GSK Enters Strategic Scientific Collaboration with Alamar Biosciences
GSK has partnered with Alamar Biosciences to utilize the NULISA platform for a large-scale study on protein signatures in various disease conditions.